United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,540,358.40. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Edgemond also recently made the following trade(s):

• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total value of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Stock Performance

United Therapeutics stock traded up $6.05 during trading on Tuesday, hitting $565.70. The company’s stock had a trading volume of 726,424 shares, compared to its average volume of 499,973. The stock’s fifty day moving average is $508.43 and its 200 day moving average is $480.83. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $607.89. The stock has a market capitalization of $24.79 billion, a price-to-earnings ratio of 20.28, a P/E/G ratio of 1.63 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the business earned $6.19 earnings per share. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. AE Wealth Management LLC increased its position in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its position in United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after acquiring an additional 2,975 shares during the period. Optimize Financial Inc acquired a new stake in United Therapeutics in the 3rd quarter valued at approximately $444,000. Simplify Asset Management Inc. acquired a new stake in United Therapeutics in the 3rd quarter valued at approximately $8,351,000. Finally, Osaic Holdings Inc. increased its position in United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after acquiring an additional 33,662 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the subject of several analyst reports. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. TD Cowen increased their price target on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a report on Monday, March 30th. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, UBS Group upped their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $586.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.